DE69034018T2 - Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts - Google Patents

Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts

Info

Publication number
DE69034018T2
DE69034018T2 DE69034018T DE69034018T DE69034018T2 DE 69034018 T2 DE69034018 T2 DE 69034018T2 DE 69034018 T DE69034018 T DE 69034018T DE 69034018 T DE69034018 T DE 69034018T DE 69034018 T2 DE69034018 T2 DE 69034018T2
Authority
DE
Germany
Prior art keywords
disease
condition
component
hyaluronic acid
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69034018T
Other languages
German (de)
English (en)
Other versions
DE69034018D1 (de
Inventor
Samuel S Asculai
Rudolf Edgar Falk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jagotec AG
Original Assignee
Jagotec AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4140639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69034018(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jagotec AG filed Critical Jagotec AG
Application granted granted Critical
Publication of DE69034018D1 publication Critical patent/DE69034018D1/de
Publication of DE69034018T2 publication Critical patent/DE69034018T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
DE69034018T 1989-09-21 1990-09-18 Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts Expired - Lifetime DE69034018T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA000612307A CA1340994C (en) 1989-09-21 1989-09-21 Treatment of conditions and disease

Publications (2)

Publication Number Publication Date
DE69034018D1 DE69034018D1 (de) 2002-12-19
DE69034018T2 true DE69034018T2 (de) 2003-07-24

Family

ID=4140639

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69034018T Expired - Lifetime DE69034018T2 (de) 1989-09-21 1990-09-18 Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
DE69024039T Expired - Lifetime DE69024039T3 (de) 1989-09-21 1990-09-18 VERWENDUNG VON HYALURONSÄURE IN KOMBINATION MIT ASCORBINSÄURE, ANTITUMORMITTELN UND/ODER NSAIDs ZUR BEHANDLUNG VON KREBS

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69024039T Expired - Lifetime DE69024039T3 (de) 1989-09-21 1990-09-18 VERWENDUNG VON HYALURONSÄURE IN KOMBINATION MIT ASCORBINSÄURE, ANTITUMORMITTELN UND/ODER NSAIDs ZUR BEHANDLUNG VON KREBS

Country Status (26)

Country Link
US (14) US6069135A (cg-RX-API-DMAC7.html)
EP (2) EP0445255B2 (cg-RX-API-DMAC7.html)
JP (1) JP3256761B2 (cg-RX-API-DMAC7.html)
KR (1) KR920700697A (cg-RX-API-DMAC7.html)
CN (1) CN1101228C (cg-RX-API-DMAC7.html)
AP (1) AP175A (cg-RX-API-DMAC7.html)
AT (2) ATE227587T1 (cg-RX-API-DMAC7.html)
AU (3) AU6433090A (cg-RX-API-DMAC7.html)
BR (1) BR9006924A (cg-RX-API-DMAC7.html)
CA (2) CA1340994C (cg-RX-API-DMAC7.html)
DE (2) DE69034018T2 (cg-RX-API-DMAC7.html)
DK (2) DK0656213T3 (cg-RX-API-DMAC7.html)
ES (2) ES2186693T3 (cg-RX-API-DMAC7.html)
FI (1) FI912470A0 (cg-RX-API-DMAC7.html)
HK (1) HK44797A (cg-RX-API-DMAC7.html)
HU (2) HU220758B1 (cg-RX-API-DMAC7.html)
IL (1) IL95745A (cg-RX-API-DMAC7.html)
IN (1) IN171745B (cg-RX-API-DMAC7.html)
LT (1) LT3545B (cg-RX-API-DMAC7.html)
NO (1) NO911952L (cg-RX-API-DMAC7.html)
RO (1) RO112812B1 (cg-RX-API-DMAC7.html)
RU (1) RU2146139C1 (cg-RX-API-DMAC7.html)
SG (1) SG49658A1 (cg-RX-API-DMAC7.html)
SK (1) SK459890A3 (cg-RX-API-DMAC7.html)
WO (1) WO1991004058A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA907564B (cg-RX-API-DMAC7.html)

Families Citing this family (248)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
DE69132145T2 (de) * 1990-02-13 2000-09-21 Ethicon Inc Peritoneal wirksame medikamente
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
CA2061566C (en) * 1992-02-20 2002-07-09 Rudolf E. Falk Treatment of disease employing hyaluronic acid and nsaids
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
US5733891A (en) * 1990-10-18 1998-03-31 Shiseido Co., Ltd. Compound for medicinal ingredient and hyaluronic acid and process for producing the same
AU652784B2 (en) * 1990-10-18 1994-09-08 Shiseido Company Ltd. Combination of hyaluronic acid with medicinal ingredient and production thereof
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
EP0503583A1 (en) * 1991-03-12 1992-09-16 Takeda Chemical Industries, Ltd. Composition for sustained release of erythropoietin
US5416071A (en) * 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
US6432405B1 (en) * 1991-03-15 2002-08-13 Duke University Method of inhibiting HIV infection with CD44 and anti-CD44 antibodies
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
US6022866A (en) * 1991-07-03 2000-02-08 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
WO1994007505A1 (en) * 1991-07-03 1994-04-14 Norpharmco Inc. Use of hyaluronic acid and forms to prevent arterial restenosis
CA2079205C (en) * 1992-09-25 1998-02-10 Rudolf Edgar Falk Use of hyaluronic acid and forms to prevent arterial restenosis
US5990095A (en) * 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
EP0522491B1 (en) * 1991-07-10 1998-11-18 Takeda Chemical Industries, Ltd. Compositions based on hyaluronic acid
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
CA2061567C (en) * 1992-02-20 1998-02-03 Rudolf E. Falk Use of hyaluronic acid to repair ischemia reperfusion damage
CA2130762C (en) * 1994-08-24 1999-07-06 Eva Anne Turley Treatment of disease and conditions associated with macrophage infiltration
US5438075A (en) 1993-03-30 1995-08-01 Skubitz; Keith M. Oral glutamine to reduce stomatitis
CA2094203A1 (en) * 1993-04-16 1994-10-17 Derek A. Willoughby Inhibition of angiogenesis
ES2106553T5 (es) * 1993-07-19 2008-02-16 Angiotech Pharmaceuticals, Inc. Composiciones anti-angiogenicas y metodos de uso.
HUT76846A (en) * 1994-08-30 1997-12-29 Hyal Pharma Corp Hyaluronic acid and derivatives for modulation of cellular activity
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
KR100517210B1 (ko) * 1994-12-12 2006-06-07 오메로스 코포레이션 통증,염증및경련억제용관주용액
ES2377126T3 (es) * 1994-12-12 2012-03-22 Omeros Corporation Solución de irrigación y utilización de la misma para la inhibición perioperatoria del dolor, la inflamación y/o los espasmos en una estructura vascular
CA2154103C (en) * 1995-07-18 1998-02-24 Samuel Simon Asculai Treatment of mucous membrane disease, trauma or condition and for the relief of pain
EP0852501B1 (en) * 1995-09-28 2004-12-01 Sangstat Medical Corporation Use of hyaluronic acid as an immunosuppressant
NZ320006A (en) * 1995-10-23 2001-12-21 Meditech Res Ltd An adjuvant composition comprising hyaluronic acid for gene therapy either in the sense or antisense direction
US5652273A (en) * 1995-11-30 1997-07-29 Henry; James Reduction of hair growth
HUP9901935A3 (en) * 1995-12-01 2001-04-28 Jagotec Ag Dosage kit for targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (gags)
US6413961B1 (en) 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
CA2166155C (en) * 1995-12-27 2008-02-05 Eva Anne Turley Agents binding to hyaluronic acid binding domains and the use thereof
DE69731610T2 (de) 1996-01-11 2005-12-01 Jagotec Ag Orale verabreichung wirksamer mengen von hyaluronsäure
US6875753B1 (en) * 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
US20050101564A1 (en) * 1996-04-02 2005-05-12 Pilarski Linda M. Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
US5939047A (en) * 1996-04-16 1999-08-17 Jernberg; Gary R. Local delivery of chemotherapeutic agents for treatment of periodontal disease
US6787530B1 (en) * 1996-08-23 2004-09-07 Monash University Use of pregnane-diones as analgesic agents
AU740111B2 (en) 1996-09-27 2001-11-01 Jagotec Ag Hyaluronic drug delivery system
US6451784B1 (en) * 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
CA2205692A1 (en) * 1997-05-16 1998-11-16 Hyal Pharmaceutical Corporation Method of administration for a therapeutic agent utilizing suitable forms of hyaluronic acid and combinations with electroporation
CA2205771C (en) * 1997-05-22 2002-05-14 Hyal Pharmaceutical Corporation Improved delivery of disease modifiers
US6123957A (en) * 1997-07-16 2000-09-26 Jernberg; Gary R. Delivery of agents and method for regeneration of periodontal tissues
US5938658A (en) * 1997-12-02 1999-08-17 Tu; Hosheng Device and methods for treating canker sores by RF ablation
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US7070799B1 (en) 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
DK1068870T3 (da) 1998-04-03 2006-10-02 Ajinomoto Kk Antitumormidler
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US6984667B2 (en) * 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
GB9810127D0 (en) * 1998-05-13 1998-07-08 Ml Lab Plc Prevention of surgical adhesions
US20020086852A1 (en) * 1998-05-14 2002-07-04 Cantor Jerome O. Method for treating respiratory disorders associated with pulmonary elastic fiber injury
US6391861B1 (en) 1998-05-14 2002-05-21 The Trustees Of Columbia University In The City Of New York Method for the prevention of tissue elastic fiber injury
US6663874B2 (en) 1998-11-02 2003-12-16 Victor Stevens Composition to alleviate pain and topical method of applying same
ATE245410T1 (de) * 1998-12-23 2003-08-15 Esparma Gmbh Mittel zum schutz der haut enthaltend hydrolysierte hyaluronsäure
ATE376824T1 (de) * 1999-01-13 2007-11-15 Alchemia Oncology Pty Ltd Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
AU773984B2 (en) * 1999-01-13 2004-06-10 Alchemia Oncology Pty Limited A composition and method for the enhancement of the efficacy of drugs
CA2361572A1 (en) * 1999-02-04 2000-08-10 Genzyme Corporation Prevention of abscess formation
DE69941359D1 (de) * 1999-02-26 2009-10-15 Maas Biolab Llc Cerebrospinal und vaskulär wirksame pharmazeutische zubereitung und verfahren zu ihrer herstellung
JP4698843B2 (ja) * 1999-05-17 2011-06-08 エーザイ インコーポレイテッド 生体活性剤の改良された細胞取り込み
JP4450456B2 (ja) * 1999-09-27 2010-04-14 株式会社マルハニチロ水産 皮脂産生抑制剤
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
JP4772245B2 (ja) * 1999-12-13 2011-09-14 バイオニケ ライフ サイエンシーズ インコーポレイテッド 治療上有用な合成オリゴヌクレオチド
CA2395493C (en) * 1999-12-28 2010-06-22 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
GB0003048D0 (en) * 2000-02-11 2000-03-29 Dealler Stephen F The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism
TR200302105T4 (tr) * 2000-04-07 2004-02-23 Laboratoire Medidom S. A. Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları.
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
EP1803730A1 (en) * 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
WO2001078721A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
US6221166B1 (en) * 2000-06-07 2001-04-24 Simplus Systems Corporation Multi-thermal zone shielding apparatus
AU9407501A (en) * 2000-06-23 2002-04-22 Medigenes Agent for reduction of scar formation by using wound alkalinization
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
US7285284B2 (en) * 2000-09-08 2007-10-23 Kuhnau Stephen C Cosmetic composition, method of use and method of making
CA2423585A1 (en) * 2000-09-26 2002-04-04 Temple University Of The Commonwealth System Of Higher Education Analgesic and glucosamine compositions
US6924273B2 (en) * 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
EA200300473A1 (ru) * 2000-10-16 2003-08-28 Неофарм, Инк. Терапевтическая композиция на основе митоксантрона (варианты) и липидный препарат, способ его получения и способ лечения заболевания млекопитающего с его использованием
EP1343502A2 (en) * 2000-11-17 2003-09-17 Idenix (Cayman) Limited Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
CN1131036C (zh) * 2001-02-28 2003-12-17 中国人民解放军第三军医大学 N－乙酰－d－氨基葡萄糖在制备抑制放化疗副反应药物中的应用
US20020172712A1 (en) * 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
WO2002074247A2 (en) * 2001-03-19 2002-09-26 Praecis Pharmaceuticals Incorporated Pharmaceutical formulations for sustained release
US20060198815A1 (en) * 2001-03-19 2006-09-07 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained release
JP5024497B2 (ja) * 2001-03-27 2012-09-12 キユーピー株式会社 経口用肌改善剤、肌改善方法及び肌改善用食品組成物
RU2284818C2 (ru) * 2001-05-10 2006-10-10 Анормед, Инк. Комбинированная химиотерапия
US8403954B2 (en) 2001-05-22 2013-03-26 Sanostec Corp. Nasal congestion, obstruction relief, and drug delivery
WO2002097038A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
RU2191012C1 (ru) * 2001-06-20 2002-10-20 Научно-исследовательский испытательный центр (медико-биологической защиты) Государственного научно-исследовательского испытательного института военной медицины МО РФ Глазные капли для лечения эндотелиально-эпителиальной дистрофии роговицы
US20030027867A1 (en) * 2001-06-29 2003-02-06 Myriad Genetics, Incorporated Use of R-NSAID compounds for anti-HIV treatment
US7544374B2 (en) * 2001-08-14 2009-06-09 Tel Aviv University Future Technology Development L.P. Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy
CA2458856C (en) * 2001-08-27 2011-02-15 Meditech Research Limited Improved therapeutic protocols
AU2002325635C1 (en) * 2001-08-27 2008-09-25 Alchemia Oncology Pty Limited Improved therapeutic protocols
EP1444983B1 (en) * 2001-10-18 2015-09-16 Seikagaku Corporation Agents for treating inflammatory bowel diseases
WO2003041723A1 (de) * 2001-11-12 2003-05-22 Reinmueller Johannes Pharmazeutische anwendungen von hyaluronsäure-präparaten
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US6806259B2 (en) 2001-12-21 2004-10-19 Soft Gel Technologies, Inc. Hyaluronic Acid in soft gel form
RU2213557C2 (ru) 2001-12-26 2003-10-10 Закрытое акционерное общество "Аксис" Фармацевтическая композиция, обладающая тромболитическими, противовоспалительными и цитопротективными свойствами
RU2232581C2 (ru) * 2002-02-05 2004-07-20 ООО НКЦ ОиН "Биотерапия" СПОСОБ ОПТИМИЗАЦИИ ПРОЦЕДУРЫ ОБЩЕЙ УПРАВЛЯЕМОЙ ГИПЕРТЕРМИИ С ТЕМПЕРАТУРОЙ РАЗОГРЕВА 43-44єC ПУТЕМ ИЗМЕРЕНИЯ ПРОТОКОЛА ХИМИОТЕРАПИИ
US7993390B2 (en) * 2002-02-08 2011-08-09 Boston Scientific Scimed, Inc. Implantable or insertable medical device resistant to microbial growth and biofilm formation
US6887270B2 (en) 2002-02-08 2005-05-03 Boston Scientific Scimed, Inc. Implantable or insertable medical device resistant to microbial growth and biofilm formation
US8506647B2 (en) * 2002-02-14 2013-08-13 Boston Scientific Scimed, Inc. System for maintaining body canal patency
WO2003070256A1 (en) * 2002-02-15 2003-08-28 Research Development Foundation Hyaluronic acid mediated adenoviral transduction
FR2836336B1 (fr) * 2002-02-26 2004-08-27 Diana Ingredients Utilisation dans un traitement cosmetique d'une fraction phenolique riche en dihydrochalcones
EP1487434B1 (en) * 2002-03-06 2007-05-09 The Medical Research and Education Trust Botanical extract compositions with anti-cancer activity comprising isoliquiritigenin
RU2222261C2 (ru) * 2002-03-22 2004-01-27 Ростовский научно-исследовательский онкологический институт Способ прицельной внутриорганной химиотерапии больных раком тела матки
RU2209634C1 (ru) * 2002-04-29 2003-08-10 Иткес Александр Веньяминович Набор эстроген-рецептор для обнаружения рецепторов к эстрогенам в биопсийных гистологических препаратах (варианты)
KR100518152B1 (ko) * 2002-05-09 2005-09-29 메디제네스(주) 혈장 또는 혈청을 함유한 창상 치료용 약학 조성물
ITMI20020986A1 (it) * 2002-05-10 2003-11-10 Acraf Composizione a base di diclofenac per il trattamento topico di affezioni del cavo orofaringeo
AU2003256381A1 (en) * 2002-07-03 2004-01-23 Pericor Science, Inc Compositions of hyaluronic acid and methods of use
CN1802152A (zh) * 2002-08-01 2006-07-12 艾斯根公司 用谷氨酰胺改善癌症的治疗
US6900173B2 (en) * 2002-09-11 2005-05-31 Kenneth A. Martin Perioperative multivitamin protein bar for use in preparing an individual for fast surgical recovery
US20040253227A1 (en) * 2002-09-11 2004-12-16 Martin Kenneth A. Perioperative multivitamin protein beverage and additive for use in preparing an individual for fast surgical recovery
US20040254095A1 (en) * 2002-09-11 2004-12-16 Martin Kenneth A. Supplement for treating musculoskeletal disorders
US20040253296A1 (en) * 2002-09-11 2004-12-16 Martin Kenneth A. Food bar for treating musculoskeletal disorders
US6979458B1 (en) 2002-09-11 2005-12-27 Kenneth A. Martin Beverage and additive for wellness
US6660308B1 (en) 2002-09-11 2003-12-09 Kenneth A. Martin Beverage and additive for the ill
DE10246340A1 (de) * 2002-10-04 2004-04-29 Wohlrab, David, Dr. Kombinationspräparat aus Hyaluronsäure und mindestens einem Lokalanästhetikum und dessen Verwendung
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US20040180025A1 (en) * 2003-03-12 2004-09-16 New Life Resources, Llc Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
US20080063677A1 (en) * 2004-03-10 2008-03-13 New Life Resources, Llc Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
US6946551B2 (en) 2003-03-12 2005-09-20 New Life Resources, Llc Preparation of hyaluronic acid from eggshell membrane
US20050136126A1 (en) * 2003-03-17 2005-06-23 Cambridgemed, Inc. Agent for reduction of scar formation by using wound alkalinization
RU2233658C1 (ru) * 2003-03-24 2004-08-10 Нижегородская государственная медицинская академия Способ профилактики кардиальных осложнений общей гипертермии с полихимиотерапией у больных с запущенными формами рака
JP4212970B2 (ja) * 2003-06-30 2009-01-21 株式会社キーエンス 安全リレーシステム
CA2532207A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
US6913968B2 (en) * 2003-07-30 2005-07-05 International Business Machines Corporation Method and structure for vertical DRAM devices with self-aligned upper trench shaping
US8236794B2 (en) * 2003-09-29 2012-08-07 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma
US20050220837A1 (en) * 2003-09-30 2005-10-06 Disegi John A Antimicrobial hyaluronic acid coatings for orthopedic implants
HUP0303313A2 (hu) * 2003-10-09 2005-07-28 Richter Gedeon Vegyészeti Gyár Rt. Transzdermális gyógyszerkészítmények
US20050196455A1 (en) * 2003-10-27 2005-09-08 Jianbing Chen Suspension delivery system for the sustained and controlled local release of pharmaceuticals
US20050100537A1 (en) * 2003-11-10 2005-05-12 Evans Gregory S. Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals
US20050147570A1 (en) * 2004-01-06 2005-07-07 Nordsiek Michael T. Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne
US7976858B2 (en) 2004-01-13 2011-07-12 The Hospital For Special Surgery Drug delivery to a joint
DE102004002001A1 (de) * 2004-01-14 2005-08-11 Reinmüller, Johannes, Dr.med. Mittel zur Behandlung von entzündlichen Erkrankungen
US20050186269A1 (en) * 2004-02-25 2005-08-25 Udell Ronald G. Stabilized feverfew formulations
US8580315B2 (en) * 2004-03-10 2013-11-12 Esm Technologies, Llc Anti-inflammatory activity of eggshell membrane and processed eggshell membrane preparations
US20060009693A1 (en) * 2004-04-08 2006-01-12 Techniscan, Inc. Apparatus for imaging and treating a breast
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
AR051429A1 (es) * 2004-04-20 2007-01-17 Stenti De Pirillo Haydee A Composicion farmaceutica ozonizada y metodos para obtenerla
EP1745180A1 (en) * 2004-04-29 2007-01-24 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
CN101267828A (zh) * 2004-06-22 2008-09-17 普罗医药公司 用于共同递送抗癌药、抗血管生成药和多糖的组合物及方法
DE102004030155B4 (de) * 2004-06-22 2020-04-23 Robert Bosch Gmbh Dosiervorrichtung und Verfahren zum Betrieb derselben
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
AU2005272578A1 (en) * 2004-08-13 2006-02-23 Angiotech International Ag Compositions and methods using hyaluronic acid and hyluronidase inhibitors
US7414021B2 (en) * 2004-10-01 2008-08-19 Vincent Carmine Giampapa Method and composition for restoration of age related tissue loss in the face or selected areas of the body
RU2259204C1 (ru) * 2004-10-12 2005-08-27 Открытое Акционерное Общество "Нижегородский Химико-Фармацевтический Завод" (Оао "Нижфарм") Средство для лечения болезней суставов
KR20070095921A (ko) 2004-12-10 2007-10-01 탈리마 테라퓨틱스 인코포레이티드 조갑 단위의 상태를 치료하기 위한 조성물 및 방법
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
US20060292250A1 (en) * 2005-06-23 2006-12-28 Suracell, Inc. Supplement composition and method of use for enhancement of anti-inflammation process
US7276257B2 (en) * 2005-07-22 2007-10-02 The Hong Kong University Of Science And Technology Schisandrin B preparation
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
WO2007012133A1 (en) 2005-07-27 2007-02-01 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
RU2292203C1 (ru) * 2005-08-17 2007-01-27 Общество с ограниченной ответственностью Медицинский центр "Эллара" (ООО МЦ "Эллара") Средство для лечения болезней суставов
US7323184B2 (en) * 2005-08-22 2008-01-29 Healagenics, Inc. Compositions and methods for the treatment of wounds and the reduction of scar formation
US20070048391A1 (en) * 2005-08-23 2007-03-01 Cambridgemed, Inc. Composition for reduction of scar formation on wound scar
US8319625B2 (en) * 2005-09-01 2012-11-27 Simplexgrinnell Lp Fire alarm textual notification related application
WO2007030623A2 (en) * 2005-09-07 2007-03-15 Amo Regional Holdings Bi-modal hyaluronate solution
EA013877B1 (ru) * 2005-09-07 2010-08-30 Алкемиа Онколоджи Пти Лимитед Терапевтические композиции, содержащие гиалуроновую кислоту и терапевтические антитела, а также способы лечения
US9492381B1 (en) 2005-11-10 2016-11-15 Reyn Pharma, Llc Method of administering hyaluronan formulation for preventing and ameliorating osteoarthritis
US8598144B1 (en) 2005-11-10 2013-12-03 Reyn Pharma, Llc Method of administering hyaluronan formulation for the amelioration of osteoarthritis
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
US7722665B2 (en) 2006-07-07 2010-05-25 Graft Technologies, Inc. System and method for providing a graft in a vascular environment
CN101522164B (zh) 2006-09-13 2014-03-26 提升肤质产品公司 用于治疗皮肤的化妆品组合物及其方法
KR101729986B1 (ko) * 2006-09-22 2017-04-25 노보 노르디스크 에이/에스 프로테아제 내성 인슐린 유사체
US20100210792A1 (en) * 2006-12-05 2010-08-19 David Taft Drug delivery
BRPI0622226A2 (pt) * 2006-12-26 2012-01-03 Romano Dev Inc composiÇço de clareamento de pele para pele hiperpigmentada
US8466128B2 (en) 2007-01-30 2013-06-18 Cypress Pharmaceuticals, Inc. Hyaluronate compositions
US8372834B2 (en) * 2007-03-02 2013-02-12 University Of Wollongong Compositions and methods for delivery of anti-cancer agents
US20080268039A1 (en) * 2007-03-06 2008-10-30 Soft Gel Technologies, Inc. Loquat compositions
WO2008143901A2 (en) * 2007-05-15 2008-11-27 Techniscan, Inc. Improved imaging system
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
HRP20180408T1 (hr) 2007-11-13 2018-04-20 Meritage Pharma, Inc. Pripravci za liječenje gastrointestinalnih upala
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
ITMI20080284A1 (it) * 2008-02-22 2009-08-23 Indena Spa Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
DK2910570T3 (en) 2008-03-18 2017-01-30 Novo Nordisk As Protease-stabilized acylated insulin analogues.
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
US8163716B1 (en) 2008-06-30 2012-04-24 Smith James D Method of administering hyaluronan formulation for the amelioration of osteophytes
US8178511B1 (en) 2008-07-02 2012-05-15 Smith James D Method of administering hyaluronan formulation for the amelioration of osteopenia
IT1397247B1 (it) * 2009-05-14 2013-01-04 Fidia Farmaceutici Nuovi agenti regolatori dell'attivita' citochinica
GB0913442D0 (en) 2009-07-31 2009-09-16 Univ Ramot Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
US8273725B2 (en) * 2009-09-10 2012-09-25 Genzyme Corporation Stable hyaluronan/steroid formulation
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
CA2806660A1 (en) 2010-07-26 2012-02-09 Chemotherapeutics, Llc Compositions and methods for enhancing the effectiveness of systemic, hipec, ip, and related cancer treatments
US8524662B2 (en) 2010-12-28 2013-09-03 Depuy Mitek, Llc Compositions and methods for treating joints
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
US8398611B2 (en) 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
KR102154944B1 (ko) 2011-06-03 2020-09-11 알러간 인더스트리 에스에이에스 항산화제를 포함하는 피부 충전제 조성물
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
TW201249843A (en) * 2011-06-14 2012-12-16 Univ Kaohsiung Medical Processes for preparing amine salts of KMUP-3 and use thereof
US8623839B2 (en) 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
HUE037474T2 (hu) * 2011-07-07 2018-08-28 Holy Stone Healthcare Co Ltd Készítmény gyulladással kapcsolatban rendellenesség kezelésében és megelõzésében történõ alkalmazásra
US20150359798A1 (en) * 2011-09-06 2015-12-17 Jansfat Biotechnology Co., Ltd. Piperazinyl derivative reduces high-fat diet-induced accumulation of fat in the livers, therapeutically
EP2567697A1 (en) 2011-09-12 2013-03-13 Almirall, S.A. Topical pharmaceutical compositions
TWI466675B (zh) * 2011-09-16 2015-01-01 Univ China Medical 用於抑制發炎之醫藥組合物
GB201118193D0 (en) 2011-10-21 2011-12-07 Jagotec Ag Improvements in or relating to oranic compounds
GB201118198D0 (en) 2011-10-21 2011-12-07 Jagotec Ag Improvements in or relating to organic compounds
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
RU2497200C1 (ru) * 2012-03-28 2013-10-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ фармакологической коррекции ишемии скелетной мышцы миноксидилом
RU2497201C1 (ru) * 2012-03-28 2013-10-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ увеличения выживаемости кожного лоскута в условиях редуцированного кровообращения миноксидилом
EP2839015B1 (en) 2012-04-18 2020-04-29 Ramot at Tel-Aviv University Ltd. Lipidated glycosaminoglycan particles for the delivery of nucleic acids
ITPD20120173A1 (it) 2012-05-31 2013-12-01 Fidia Farmaceutici "nuovo sistema di rilascio di proteine idrofobiche"
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ITMI20121316A1 (it) 2012-07-27 2014-01-28 Altergon Sa Complessi di condroitina ad assorbimento transcutaneo
FR2994846B1 (fr) 2012-08-29 2014-12-26 Vivacy Lab Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
FR3000670B1 (fr) * 2013-01-10 2015-02-27 Oreal Composition cosmetique apaisante a base d'acide salicylique.
WO2014159060A1 (en) 2013-03-14 2014-10-02 Hallux, Inc. Method of treating infections, diseases or disorders of nail unit
CN105120889B (zh) 2013-04-03 2018-04-13 雪松-西奈医学中心 通过调节乙酰透明质酸和透明质酸酶活性而治疗炎性病状
GR1008308B (el) 2013-05-31 2014-10-02 UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE", Τοπικες φαρμακευτικες και ιατροτεχνολογικες συνθεσεις που περιεχουν συνδυασμους σουκραλφατης, υαλουρονικου οξεος, αργινινης και ενος φυσικου ενυδατικου παραγοντα
KR101439032B1 (ko) * 2013-06-13 2014-09-05 동아에스티 주식회사 피록시캄과 히알루론산을 포함하는 골관절염 치료를 위한 액상 조성물
CN103330945B (zh) * 2013-07-16 2014-07-02 山东大学齐鲁医院 平阳霉素联合透明质酸钠在治疗淋巴管畸形药物中的应用
CN103341157A (zh) * 2013-07-25 2013-10-09 山东大学齐鲁医院 平阳霉素联合透明质酸钠在治疗静脉畸形药物中的应用
MX366636B (es) 2013-10-07 2019-07-17 Novo Nordisk As Nuevo derivado de un análogo de insulina.
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
US10583084B2 (en) 2014-06-26 2020-03-10 Ramot At Tel-Aviv University Ltd. Liposomal formulations for delivery of nucleic acids
US9682099B2 (en) 2015-01-20 2017-06-20 DePuy Synthes Products, Inc. Compositions and methods for treating joints
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
TWI700091B (zh) 2016-12-16 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 含胰島素醫藥組成物
WO2019173261A1 (en) * 2018-03-06 2019-09-12 Samuel Asculai Composition and method to treat cancer using hyaluronic acid
CN109512825A (zh) * 2018-12-29 2019-03-26 江苏靶标生物医药研究所有限公司 一种铂类化合物和透明质酸钠的组合物及其应用
CN110467689A (zh) * 2019-09-09 2019-11-19 山东众山生物科技有限公司 一种透明质酸衍生物及其制备方法
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583096A (en) * 1949-01-15 1952-01-22 Searle & Co Process for the production of high viscosity hyaluronic acid
GB769287A (en) * 1954-08-18 1957-03-06 American Home Prod Preparation of partially depolymerized hyaluronic acid and therapeutic compositions thereof
FR3715M (fr) * 1964-06-11 1965-11-29 Lucien Nouvel Antithermiques et antirhumatismaux améliorés.
US3887703A (en) * 1967-03-24 1975-06-03 Oreal Mucopolysaccharides, their preparation and use in cosmetic and pharmaceutical compositions
GB1283892A (en) * 1970-06-08 1972-08-02 Irwin Irville Lubowe Improvements in and relating to medicinal compositions for application to the skin and/or hair
DE2364373A1 (de) * 1973-12-22 1975-07-10 Hahn Carl Dr Gmbh Pharmazeutische und kosmetische praeparate zur aeusserlichen anwendung
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4282216A (en) * 1977-04-20 1981-08-04 Johnson & Johnson Topical anti-inflammatory drug therapy
US4296104A (en) * 1979-08-30 1981-10-20 Herschler R J Therapeutic dimethyl sulfoxide composition and methods of use
US4272522A (en) * 1979-10-15 1981-06-09 Balazs Endre A Method for stimulating phagocytic activity and synergistic compositions therefor
US4303676A (en) * 1980-03-21 1981-12-01 Balazs Endre A Hyaluronate based compositions and cosmetic formulations containing same
US4434177A (en) * 1980-04-14 1984-02-28 Merck & Co., Inc. α-Methyldopa-L-ascorbic acid compositions
JPS57183707A (en) * 1981-05-02 1982-11-12 Shiseido Co Ltd Cosmetic
US4684627A (en) * 1981-09-08 1987-08-04 Leveen Harry H Treatment of cancer with phlorizin and its derivatives
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4582685A (en) 1982-10-07 1986-04-15 Helena Laboratories Corporation Test kit for performing a medical test
US4711884A (en) * 1983-02-28 1987-12-08 E. R. Squibb & Sons, Inc. Thiazine and thiazepine containing compounds
AU555747B2 (en) * 1983-08-09 1986-10-09 Cilco Inc. Chondroitin sulfate and sodium hyaluronate composition
AU570998B2 (en) * 1983-09-07 1988-03-31 Takeda Chemical Industries Ltd. Topical steroid compositions for acne
IN163192B (cg-RX-API-DMAC7.html) * 1983-10-11 1988-08-20 Fidia Spa
IL74715A0 (en) * 1984-03-27 1985-06-30 Univ New Jersey Med Biodegradable matrix and methods for producing same
CH663353A5 (de) * 1984-03-28 1987-12-15 Joaquin Amat Larraz Mittel gegen krebs.
US4716224A (en) * 1984-05-04 1987-12-29 Seikagaku Kogyo Co. Ltd. Crosslinked hyaluronic acid and its use
US4711780A (en) * 1984-06-11 1987-12-08 Fahim Mostafa S Composition and process for promoting epithelial regeneration
JPS6117A (ja) * 1984-06-11 1986-01-06 Seikagaku Kogyo Co Ltd ムコ多糖系癌転移抑制剤
US4735902A (en) * 1984-10-23 1988-04-05 Matti Siren Stabilized composition containing inositoltriphosphate
US4582865A (en) * 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4636524A (en) * 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
DE3686275T2 (de) * 1985-01-11 1993-03-18 Teijin Ltd Praeparate mit verzoegerter freisetzung.
SE8501723L (sv) * 1985-04-09 1986-10-10 Pharmacia Ab Preparation att anvendas vid behandling av ledinflammation
JPS61233622A (ja) * 1985-04-09 1986-10-17 Riken Vitamin Co Ltd 眼薬組成物
US4725585A (en) * 1985-04-26 1988-02-16 Pharmacia Ab Method of enhancing the host defense
US4725852A (en) 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
IT1214609B (it) * 1985-05-17 1990-01-18 Opocrin Spa Esosaminoglicani solfati depolimerizzati ad attivita'antitrombotica, fibrinolitica, antinfiammatoria, loro procedimento di preparazione e composizioni farmaceutiche che li contengono.
EP0207638B1 (en) * 1985-06-04 1990-12-19 Teijin Limited Sustained-release pharmaceutical preparation
US4617319A (en) * 1985-06-13 1986-10-14 American Cyanamid Company Method of treating multiple sclerosis
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
FR2584606A1 (fr) * 1985-07-12 1987-01-16 Dropic Utilisation de poly- et oligosaccharides pour l'obtention de medicaments actifs dans les pathologies du tissu conjonctif
IN166447B (cg-RX-API-DMAC7.html) * 1985-11-27 1990-05-12 Ethicon Inc
EP0224987B1 (en) * 1985-11-29 1992-04-15 Biomatrix, Inc. Drug delivery systems based on hyaluronan, derivatives thereof and their salts and method of producing same
JP2604135B2 (ja) * 1986-02-28 1997-04-30 ライオン株式会社 口腔骨疾患治療剤
US5262403A (en) * 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
JPS62212335A (ja) * 1986-03-14 1987-09-18 Mitsui Toatsu Chem Inc ２−アリ−ル−２−メチルプロピルエ−テル誘導体およびそれを有効成分として含有する殺虫剤
JPS62240628A (ja) * 1986-03-26 1987-10-21 Kao Corp 経皮吸収促進剤およびこれを含有する外用剤
EP0240098A3 (en) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
JPS6345223A (ja) * 1986-04-04 1988-02-26 Ueno Seiyaku Oyo Kenkyusho:Kk ひと免疫不全ウイルス性疾患処置剤
AU604236B2 (en) * 1986-04-28 1990-12-13 Iolab, Inc. Intraocular dosage compositions and method of use
US4808576A (en) * 1986-04-28 1989-02-28 Mobay Corporation Remote administration of hyaluronic acid to mammals
JPH06104624B2 (ja) * 1986-05-07 1994-12-21 太郎 小木曽 経皮吸収剤
IT1189111B (it) * 1986-05-08 1988-01-28 Minnesota Mining & Mfg Elementi radiografici con un ridotto cross-over e ridotta colorazione residua
JPS62287041A (ja) * 1986-06-05 1987-12-12 Kawasaki Steel Corp 高合金鋼焼結材料の製造方法
US4946870A (en) * 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
JPS6311678A (ja) 1986-06-30 1988-01-19 Hitachi Chem Co Ltd 無電解銅めつき法
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
IT1198449B (it) * 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
JPH07110349B2 (ja) * 1986-11-04 1995-11-29 セイレイ工業株式会社 籾摺選別装置
ZA878877B (en) * 1986-11-29 1988-05-24 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Treatment of diseases caused by viruses
EP0270319A3 (en) * 1986-12-03 1990-03-28 Logistics Data Systems, Inc. Video c.a.d. system
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
GB8706052D0 (en) * 1987-03-13 1987-04-15 Medical Research Int Therapeutic compositions
CA1327354C (en) * 1987-03-19 1994-03-01 David Cullis-Hill Anti-inflamatory compounds and compositions
EP0285357A3 (en) * 1987-03-31 1989-10-25 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Control of retroviruses
US4795741A (en) * 1987-05-06 1989-01-03 Biomatrix, Inc. Compositions for therapeutic percutaneous embolization and the use thereof
US5079236A (en) * 1987-05-27 1992-01-07 Hyal Pharmaceutical Corporation Pure, sterile, pyrogen-free hyaluronic acid formulations their methods of preparation and methods of use
GB8713662D0 (en) * 1987-06-11 1987-07-15 Skandigen Ab Hyaluronic acid derivatives
GB8713747D0 (en) * 1987-06-12 1987-07-15 Unilever Plc Skin treatment composition
GB8715242D0 (en) * 1987-06-29 1987-08-05 Wood E M Fenclofenac as immunosuppressant drug
PT87886B (pt) * 1987-07-01 1993-09-30 Genentech Inc Metodo para a prevencao de deposicao de fibrina ou de formacao de adesoes e processo para a preparacao de composicoes terapeuticas para esse fim
US4900550A (en) * 1987-08-19 1990-02-13 Amy Allene Cosmetiques, Inc. Skin care cosmetic regime
EP0391909B1 (en) * 1987-09-03 1994-08-17 The University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
EP0307097B1 (en) * 1987-09-08 1993-06-09 Takeda Chemical Industries, Ltd. Water-insolubilized cytokines
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
HU203198B (en) * 1987-10-26 1991-06-28 Sandoz Ag Process for producing pharmaceutical compositions having immunity-inhibiting, monokin-, particularly interleukin-1-inhibiting effect
JPH01151462A (ja) * 1987-12-09 1989-06-14 Terumo Corp 腹膜灌流液
DK505488D0 (da) * 1987-12-21 1988-09-09 Bar Shalom Daniel Middel og anvendelse af samme
DK505588D0 (da) * 1988-02-26 1988-09-09 Jesper Hamburger Middel og anvendelse af samme
US4943560A (en) * 1988-04-06 1990-07-24 Regents Of The University Of Minnesota Solvent system for chronic vascular infusion of hydrophobic drugs
JPH01265970A (ja) * 1988-04-19 1989-10-24 Shiseido Co Ltd ヒアルロン酸を含有させたコラーゲン水溶液又は水分散液
US4840341A (en) 1988-05-09 1989-06-20 Hasegawa Gary K Clip and holder
JPH01287041A (ja) * 1988-05-13 1989-11-17 Rooman Kogyo:Kk 徐放性製剤
IT1219587B (it) * 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
US5135915A (en) * 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
DE3900198A1 (de) * 1989-01-05 1990-07-12 Merck Patent Gmbh Topisch anwendbare pharmazeutische zubereitung
US5032384A (en) * 1989-01-27 1991-07-16 Block Drug Company, Inc. Compositions and method for the treatment of disease
US5156846A (en) * 1989-02-23 1992-10-20 University Of Utah Percutaneous drug delivery system
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5053222A (en) * 1989-06-07 1991-10-01 Shiseido Company Ltd. Hair cosmetic composition
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
US5181276A (en) * 1990-02-22 1993-01-26 Baxter International Inc. Infection resistant products
US5290271A (en) * 1990-05-14 1994-03-01 Jernberg Gary R Surgical implant and method for controlled release of chemotherapeutic agents
US5091182A (en) * 1990-07-23 1992-02-25 Syntex (U.S.A.) Inc. Dispensing units for ketorolac topical gel formlations
US5234914A (en) * 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
JP3262620B2 (ja) * 1992-02-04 2002-03-04 バクスター・インターナショナル・インコーポレイテッド 腹膜炎によって生ずる傷害および生理学的副作用を最小にするために使用し得る腹膜透析液

Also Published As

Publication number Publication date
JP3256761B2 (ja) 2002-02-12
CA2042034A1 (en) 1991-03-22
US6069135A (en) 2000-05-30
AU1485097A (en) 1997-05-22
FI912470A7 (fi) 1991-05-21
EP0656213B1 (en) 2002-11-13
US5811410A (en) 1998-09-22
FI912470A0 (fi) 1991-05-21
AU6433090A (en) 1991-04-18
CA1340994C (en) 2000-05-16
DE69024039T3 (de) 2002-12-12
HK44797A (en) 1997-04-18
EP0445255B1 (en) 1995-12-06
NO911952D0 (no) 1991-05-21
RU2146139C1 (ru) 2000-03-10
HK1005985A1 (en) 1999-02-05
ATE227587T1 (de) 2002-11-15
US5914314A (en) 1999-06-22
ES2080837T3 (es) 1996-02-16
JPH04504579A (ja) 1992-08-13
US20060128655A1 (en) 2006-06-15
US5830882A (en) 1998-11-03
HU211953A9 (en) 1996-01-29
US5827834A (en) 1998-10-27
ZA907564B (en) 1991-08-28
IN171745B (cg-RX-API-DMAC7.html) 1992-12-26
SK459890A3 (en) 2000-09-12
HUT64699A (en) 1994-02-28
IL95745A (en) 1999-09-22
EP0445255B2 (en) 2001-12-05
US5929048A (en) 1999-07-27
EP0445255A1 (en) 1991-09-11
US5985851A (en) 1999-11-16
CN1051503A (zh) 1991-05-22
US5852002A (en) 1998-12-22
AU674894C (en) 2002-03-14
RO112812B1 (ro) 1998-01-30
LTIP1582A (en) 1995-06-26
LT3545B (en) 1995-11-27
NO911952L (no) 1991-07-05
US6048844A (en) 2000-04-11
DE69024039T2 (de) 1996-06-13
AP175A (en) 1992-04-03
US5985850A (en) 1999-11-16
DK0445255T4 (da) 2002-02-18
EP0656213A1 (en) 1995-06-07
US5932560A (en) 1999-08-03
DE69034018D1 (de) 2002-12-19
AU674894B2 (en) 1997-01-16
ES2186693T3 (es) 2003-05-16
CN1101228C (zh) 2003-02-12
US20040019011A1 (en) 2004-01-29
DE69024039D1 (de) 1996-01-18
WO1991004058A3 (en) 1991-09-19
HU907339D0 (en) 1991-08-28
WO1991004058A2 (en) 1991-04-04
SG49658A1 (en) 1998-06-15
AP9000206A0 (en) 1990-10-31
DK0445255T3 (da) 1996-03-04
US6194392B1 (en) 2001-02-27
BR9006924A (pt) 1991-12-10
DK0656213T3 (da) 2003-03-17
ATE131068T1 (de) 1995-12-15
ES2080837T5 (es) 2002-03-01
KR920700697A (ko) 1992-08-10
AU5227493A (en) 1994-03-03
IL95745A0 (cg-RX-API-DMAC7.html) 1991-06-30
HU220758B1 (hu) 2002-05-28

Similar Documents

Publication Publication Date Title
DE69034018T2 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
DE69330180T2 (de) Hyaluronsäure enthaltende formulierungen
DE69333072T2 (de) Topisch anzuwendendes arzneimittel enthaltend hyaluronsäure und nsaids
EP2099462B1 (de) Pharmazeutische zubereitung für die behandlung entzündlicher erkrankungen des urogenitaltraktes
JP2002511057A (ja) 局所薬剤製剤
DE69630974T2 (de) Hyaluronsäurerezeptoren bindende stoffe und deren verwendung zur behandlung von tumoren und restenose
DE10360425A1 (de) Verwendung von Hyaluronsäure, Hyaluronat und/oder deren Derivate zur Herstellung einer pharmazeutischen Zusammensetzung
WO1998052613A2 (en) Method of administration for a therapeutic agent utilizing suitable forms of hyaluronic acid and combinations with electroporation
HK1005985B (en) Combined use of hyaluronic acid and therapeutic agents to improve the therapeutic effect
AU6173599A (en) Treatment of conditions and disease
CZ288292B6 (en) Compound therapeutic preparations intended for treatment of diseases or states of tissues comprising insufficiently perfused tissues and pathological tissues of human being

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: MEISSNER, BOLTE & PARTNER GBR, 80538 MUENCHEN